Review Articles

2021  |  Vol: 7(2)  |  Issue: 7 (March-April)  |
Clinical perspectives of Janus Kinase Inhibitors: A review

Sadanand R. Mallurwar1*, Vinod K. Nakra2, Mahesh R. Bhat3

1Mandsaur University, Mandsaur- 458001 (M.P.) India

2Faculty of Pharmacy B. R. Nahata college of Pharmacy, Mandsaur University, Mandsaur- 458001(M.P.) India

3Nuper Therapeutics A division of Jain Pharmaceuticals, Off. No. 106, Nyati Emporious, Near Balewadi Stadium, Baner, Pune-411045 (M.S.) India

*Address for Corresponding Author

Sadanand R. Mallurwar, M. Pharm.

Department of Pharmaceutical Sciences, Mandsaur University, Mandsaur- 458001, Madhya Pradesh, India


JAK inhibitors are small-molecule drugs that inhibit Janus kinases (Jakinibs) widely used in multiple therapeutic areas like rheumatoid arthritis, psoriasis, inflammatory bowel disease, cancer and recently tried with antiviral agents for COVID-19 treatment and have gained traction as safe and efficacious options for these treatments. The JAK inhibitors are considered as new players in many treatments hence this review highlights the use of major JAK inhibitors in various therapeutic areas; their uses and associated risk and limitations in clinical settings. For collection of clinical data recent articles were taken in consideration.

Keywords: Janus kinase inhibitors, JAK-STAT pathway, tyrosine kinase-2, tofacitinib, rheumatoid arthritis

Manuscript Management System
Submit Article Subscribe Most Popular Articles Join as Reviewer Email Alerts Open Access
Our Another Journal
Another Journal
Call for Paper in Special Issue on

Call for Paper in Special Issue on